The ELANE Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma cell line, in which the ELANE gene has been disrupted to create a loss-of-function model. This polyclonal format provides a heterogeneous pool of cells carrying various gene disruptions, avoiding clonal selection bias and serving as a robust tool for functional studies.
The parental A2780 cell line, established from an untreated ovarian adenocarcinoma, is a widely accepted model for ovarian cancer research. It exhibits epithelial morphology, hormone responsiveness, and the ability to form xenograft tumors, making it suitable for investigations into cancer cell signaling, drug resistance, and the tumor microenvironment. Its well-characterized genetic and phenotypic features facilitate reproducible experimental designs.
ELANE encodes neutrophil elastase, a serine protease that degrades extracellular matrix components such as elastin, collagen, and fibronectin, and proteolytically processes pro-inflammatory cytokines including IL-1?? and TNF-??. Its transcription is regulated by CEBPA, SPI1, and GFI1 downstream of G-CSF, and its enzymatic activity is tightly controlled by the endogenous inhibitors SERPINA1 (??1-antitrypsin), elafin, and SLPI. Downstream, elastase-mediated cleavage contributes to the activation of TLR4, NF-??B, and MAPK signaling cascades, and stimulates matrix metalloproteinase (MMP)-mediated extracellular matrix degradation. In malignancy, these processes promote tumor cell invasion, local inflammation, and stromal remodeling.
In the A2780 ovarian cancer context, knockout of ELANE eliminates neutrophil elastase activity, thereby disrupting the degradation of extracellular matrix proteins and the processing of key cytokines. This provides a defined system to interrogate elastase-dependent contributions to tumor cell invasion, inflammatory signaling, and crosstalk with stromal cells, and to clarify how ELANE influences ovarian cancer aggressiveness and immune evasion. Additionally, the model permits investigation of how loss of elastase affects downstream targets such as TLR4 and NF-??B activation.
These polyclonal knockout cells are ideally suited for migration and invasion assays to assess ECM degradation-dependent phenotypes, co-culture experiments with neutrophils to recapitulate tumor-immune interactions, and elastase inhibitor screening campaigns. Drug discovery applications include screening elastase inhibitors or compounds targeting downstream effectors. Routine validation methods encompass western blotting, quantitative RT-PCR, and zymography, complemented by immunofluorescence and flow cytometry to assess inflammatory and signaling readouts. This knockout tool also facilitates exploration of ELANE-associated pathways in neutrophil disorders such as severe congenital neutropenia. For technical inquiries, please contact Ascent Research.
